MedPath

A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndrome

Not Applicable
Conditions
Refractory nephrotic syndrome
Registration Number
JPRN-UMIN000021143
Lead Sponsor
Fujita Health University School of Medicine, Department of Nephrology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

1. Severe hypersensitivity to the component of rituximab or products derived from mouse protein. 2. Positive serology for HBs antigen or HBv-DNA 3. Active infection

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath